Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial

A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial

(2021) Mahn-Won Park et al.   EuroIntervention

Guided P2Y12 inhibitor therapy after percutaneous coronary intervention

(2021) Dirk Sibbing et al.   LANCET

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

(2021) Mattia Galli et al.   LANCET

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2020) Jean-Philippe Collet et al.   EUROPEAN HEART JOURNAL

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial

(2020) Hyo-Soo Kim et al.   LANCET

Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals

(2019) Behnood Bikdeli et al.   CIRCULATION

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention

(2019) Dirk Sibbing et al.   JACC-Cardiovascular Interventions

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

(2019) Joo-Yong Hahn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

(2019) Roxana Mehran et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI

(2019) Daniel M.F. Claassens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

(2019) Kuniaki Takahashi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor

(2018) Zuzana Motovska et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

(2018) Pascal Vranckx et al.   LANCET

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study

(2017) Thomas Cuisset et al.   EUROPEAN HEART JOURNAL

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

(2017) Dirk Sibbing et al.   LANCET

Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry

(2017) Leonardo De Luca et al.   EuroIntervention

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

(2016) Glenn N. Levine et al.   CIRCULATION

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention

(2016) Matthijs A Velders et al.   HEART

Adherence to Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review

(2014) Matthew J. Czarny et al.   CLINICAL CARDIOLOGY

Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy

(2014) Antonio Colombo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina

(2013) Ho-Sook Kim et al.   Circulation-Cardiovascular Genetics

Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

(2012) Gjin Ndrepepa et al.   CIRCULATION

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

(2011) R. C. Becker et al.   EUROPEAN HEART JOURNAL

Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes

(2009) Gjin Ndrepepa et al.   CARDIOLOGY

Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2009) David A. Morrow et al.   CIRCULATION

Medication Adherence

(2009) P. Michael Ho et al.   CIRCULATION

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

(2008) Elliott M. Antman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY